Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


W. R. Grace artificial liver

This article was originally published in The Gray Sheet

Executive Summary

W. R. Grace and Cedars-Sinai Medical Center of Los Angeles begin clinical study of a bioartificial liver system following FDA approval of an investigational new drug application for the system. The bioartificial liver, developed jointly by Grace and Cedars under an agreement announced in November ("The Gray Sheet" Nov. 22, 1993, In Brief), consists of "a hollow-fiber membrane cartridge filled with a matrix of pig liver cells" and is intended to act as a short-term bridge to transplant for patients with acute and chronic liver failure. The first phase of the trial will involve 12-20 patients and will take place at Cedars, with Phase II trials expected to begin in mid-1995



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts